Celltrion and Teva Report Results Updated Results of CT-P6 in P-III Study for Patients Receiving Neoadjuvant Treatment for HER2-Positive Early Breast Cancer

 Celltrion and Teva Report Results Updated Results of CT-P6 in P-III Study for Patients Receiving Neoadjuvant Treatment for HER2-Positive Early Breast Cancer

Celltrion Reports Results of CT-P13 SC (infliximab, biosimilar) in a Clinical Study for Rheumatoid Arthritis #EULAR2019

Shots:

  • The study involves assessing of CT-P6 vs reference trastuzumab in 516 patients neoadjuvant period of the study entered the adjuvant treatment period
  • The study resulted in 9 patients (3.3%) in the biosimilar group and 6 patients (2.2%) in the reference group in the ITT population had recurrent or progressive disease @1 year. In adjuvant period relative dose intensity trastuzumab was 98.5% (2.97) and 98.8% (2.27) in the biosimilar and reference groups 
  • CT-P6 is a mAb targeted for a protein designed to recognize and bind to a specific structure or antigen in the body and is targeted to treat Neoadjuvant Treatment for HER2-Positive Early Breast Cancer

Click here to read full press release/ article | Ref: Center For Biosimilars| Image: Celltrion

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post